Abstract
ADAM28 is a member of the ADAM (a disintegrin and metalloproteinase) gene family and consists of two isoforms, prototype membrane-type form and short secreted form. The metalloproteinase domain of ADAM28 has the zincbinding consensus sequence, andADAM28 exhibits catalytic activity to a few substrates such as insulin-like growth factor binding protein-3. The disintegrin domain interacts with integrins α4β1, α4β7 and α9β1. In human non-small cell lung carcinomas and breast carcinomas, ADAM28 is overexpressed predominantly by carcinoma cells, and the expression correlates with carcinoma cell proliferation and lymph node metastasis. In this review we present our data on the activation of proADAM28, the tissue localization in human cancers and the interaction molecules, and discuss the regulation of ADAM28 activity and gene expression, the functions of ADAM28 in human cancers and the possibility of ADAM28 as a target for cancers.
Keywords: ADAM28, proliferation, invasion, metastasis, MMP, IGFBP-3, PSGL-1, integrin
Current Pharmaceutical Design
Title: ADAM28 as a Target for Human Cancers
Volume: 15 Issue: 20
Author(s): Satsuki Mochizuki and Yasunori Okada
Affiliation:
Keywords: ADAM28, proliferation, invasion, metastasis, MMP, IGFBP-3, PSGL-1, integrin
Abstract: ADAM28 is a member of the ADAM (a disintegrin and metalloproteinase) gene family and consists of two isoforms, prototype membrane-type form and short secreted form. The metalloproteinase domain of ADAM28 has the zincbinding consensus sequence, andADAM28 exhibits catalytic activity to a few substrates such as insulin-like growth factor binding protein-3. The disintegrin domain interacts with integrins α4β1, α4β7 and α9β1. In human non-small cell lung carcinomas and breast carcinomas, ADAM28 is overexpressed predominantly by carcinoma cells, and the expression correlates with carcinoma cell proliferation and lymph node metastasis. In this review we present our data on the activation of proADAM28, the tissue localization in human cancers and the interaction molecules, and discuss the regulation of ADAM28 activity and gene expression, the functions of ADAM28 in human cancers and the possibility of ADAM28 as a target for cancers.
Export Options
About this article
Cite this article as:
Mochizuki Satsuki and Okada Yasunori, ADAM28 as a Target for Human Cancers, Current Pharmaceutical Design 2009; 15 (20) . https://dx.doi.org/10.2174/138161209788682424
DOI https://dx.doi.org/10.2174/138161209788682424 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemokines and Their Receptors: Potential Therapeutic Targets for Bone Cancer Pain
Current Pharmaceutical Design Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Down Regulation of Differentiated Embryo-Chondrocyte Expressed Gene 1 is Related to the Decrease of Osteogenic Capacity
Current Drug Targets Role of microRNAs in Osteoblasts Differentiation and Bone Disorders
Current Medicinal Chemistry Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics
Current Medicinal Chemistry Application of Molecular Imaging Technologies in Antitumor Drug Development and Therapy
Current Pharmaceutical Design Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design Natural Compounds and Drug Discovery: Can Cnidarian Venom Play a Role?
Central Nervous System Agents in Medicinal Chemistry Melanoma and Epigenetic Treatment: Past and Future
Anti-Cancer Agents in Medicinal Chemistry Hypoxic Regulation of Metastasis via Hypoxia-Inducible Factors
Current Molecular Medicine Non-Primate EIAV-Based Lentiviral Vectors as Gene Delivery System for Motor Neuron Diseases
Current Gene Therapy Effect of Oil Extract from Microalgae (<i>Schizochytrium</i> sp.) on the Viability and Apoptosis of Human Osteosarcoma Cells
Current Pharmaceutical Biotechnology Insulin Like Growth Factor-I: A Critical Mediator of the Skeletal Response to Parathyroid Hormone
Current Molecular Pharmacology Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach
Current Gene Therapy Roles of NHERF1/EBP50 in Cancer
Current Molecular Medicine AMPK as a Potential Anticancer Target - Friend or Foe?
Current Pharmaceutical Design Novel Orphan Nuclear Receptors-Coregulator Interactions Controlling Anti-Cancer Drug Metabolism
Current Drug Metabolism Implantable (Bio)Polymer Coated Titanium Scaffolds: A Review
Current Pharmaceutical Design Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy High Content Screening for G Protein-Coupled Receptors Using Cell-Based Protein Translocation Assays
Combinatorial Chemistry & High Throughput Screening